Greater IOL lowering
The IOP-lowering effect of FDC netarsudil/latanoprost was also greater than with either netarsudil or latanoprost at the month 6, 9, and 12 follow-up visits. In addition, an efficacy analysis of the proportion of patients with a mean month 12 diurnal IOP ≤14 mm Hg, ≤15 mm Hg, ≤16 mm Hg, ≤17 mm Hg, and ≤18 mm Hg consistently found a statistically significant difference favoring the FDC group versus the 2 control groups.
At month 12, 82% of patients in the FDC netarsudil/latanoprost group compared with 57% of patients using netarsudil alone and 66% of latanoprost-treated patients had a mean diurnal IOP ≤18 mm Hg, Dr. Brubaker reported.
“Netarsudil is a novel product that is only recently available to our patients as a stand-alone agent,” Dr. Brubaker said. “The fixed-dose combination product would improve compliance with once-a-day dosing and was shown to be remarkably effective. With regards to the data and efficacy, I’m most excited by the proportion of patients who achieved a quite low IOP using the combination product.”